Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
12.10
Oct 20 • 3:59 PM ET Dollar change-0.60 Percentage change(-4.72%)
Aftermarket Close
12.10
Aftermarket • 7:30 PM ET Dollar change0.00 Percentage change(0.00%)
Index
RUT
Market Cap
156.21M
Enterprise Value
130.41M
Income
-20.18M
Sales
11.86M
Book/sh
2.76
Cash/sh
2.74
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
121
IPO
Mar 20, 2014
P/E
-
Forward P/E
-
PEG
-
P/S
13.17
P/B
4.38
P/C
4.42
P/FCF
-
EV/EBITDA
-
EV/Sales
11.00
Quick Ratio
2.09
Current Ratio
2.32
Debt/Eq
0.27
LT Debt/Eq
0.24
Option/Short
Yes / Yes
EPS (ttm)
-1.60
EPS next Y
-2.20
EPS next Q
-0.71
EPS this Y
-4.37%
EPS next Y
-0.30%
EPS next 5Y
16.86%
EPS past 3/5Y
18.87% 2.36%
Sales past 3/5Y
-13.82% -4.87%
EPS Y/Y TTM
39.18%
Sales Y/Y TTM
-40.26%
EPS Q/Q
53.32%
Sales Q/Q
-45.83%
Insider Own
25.52%
Insider Trans
0.12%
Inst Own
53.87%
Inst Trans
0.49%
ROA
-29.06%
ROE
-72.37%
ROIC
-45.60%
Gross Margin
15.46%
Oper. Margin
-271.59%
Profit Margin
-170.10%
SMA20
-6.91%
SMA50
-8.32%
SMA200
-21.70%
Trades
Shs Outstand
12.91M
Shs Float
9.62M
52W High
20.03 -39.59%
52W Low
11.84 2.20%
Volatility
4.90% 3.69%
ATR (14)
0.51
RSI (14)
39.83
Beta
0.07
Rel Volume
2.72
Avg Volume
85.71K
Volume
233,114
Perf Week
-0.98%
Perf Month
-9.09%
Perf Quarter
-16.09%
Perf Half Y
-27.11%
Perf YTD
-34.45%
Perf Year
-38.55%
Perf 3Y
49.38%
Perf 5Y
-52.51%
Perf 10Y
-74.01%
Prev Close
12.70
Price
12.10
Change %
-4.72%
Date Action Analyst Rating Change Price Target Change
Jun-02-25Resumed Oppenheimer Outperform $34
May-02-25Initiated Alliance Global Partners Buy $25
Feb-28-25Initiated Craig Hallum Buy $39
Jul-16-24Reiterated Maxim Group Buy $25 → $30
Dec-22-22Initiated Maxim Group Buy $11
Jul-18-22Resumed Oppenheimer Outperform $7
Sep-23-20Initiated BTIG Research Buy $6
Nov-28-16Initiated Aegis Capital Buy $11
Aug-17-16Initiated Wells Fargo Outperform
Apr-16-14Initiated Oppenheimer Outperform $25
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rubinstein SamuelDirectorSep 01 '26Buy12.625256,626525Sep 02 04:02 PM
Rubinstein SamuelDirectorSep 01 '26Sale12.725256,6780Sep 02 04:02 PM
Hess ShmuelCOO & Chief Commercial OfficerAug 27 '26Sale12.923,95851,1490Aug 28 04:02 PM
Hess ShmuelCOO & Chief Commercial OfficerAug 26 '26Sale13.001,86524,2450Aug 28 04:02 PM
Shmulik HessOfficerAug 27 '26Proposed Sale12.703,95850,267Aug 28 06:36 AM
SHAMIR NACHUMDirectorJun 03 '26Buy14.006,00083,99655,815Jun 04 04:05 PM
Fox David MortonDirectorJun 01 '26Buy14.113,53749,90122,283Jun 02 07:30 AM
Rubinstein SamuelDirectorMay 29 '26Buy14.331502,1502,993Jun 01 07:00 AM
Hess ShmuelOfficerDec 02 '25Proposed Sale17.213,69363,557Dec 03 07:44 AM
MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product NexoBrid, is an orphan biologic for eschar removal in severe burns. The company was founded by Lior Rosenberg and Marian Gorecki in January 2000 and is headquartered in Yavne, Israel.
Chief Executive OfficerMr. Ofer Gonen B.Sc.
Chief Financial OfficerMs. Hani Luxenburg
COO & Chief Commercial OfficerDr. Shmulik Hess Ph.D.
Executive VPMr. Yaron Meyer Adv.
Ph.D.Dr. Ety Klinger MBA